The Food and Drug Administration rarely uses its authority to pull dangerous medical devices off the shelves and is so poorly staffed that it’s unable to make sure companies are taking critical steps to protect patients during health crises, according to a new report by the Government Accountability Office.
The inquiry by the congressional watchdog was requested nearly two years ago by top members of the U.S. Senate in the wake of an investigation about the 2021 recall of breathing machines that threatened the health of millions of Americans.
The Pittsburgh Post-Gazette and ProPublica revealed that the FDA had received hundreds of complaints over many years about the machines made by Philips Respironics, which operated two sprawling facilities near Pittsburgh and was once among the largest device makers in the country.
Philips eventually recalled the machines, which were fitted with an industrial foam capable of breaking down and releasing toxic material into the lungs of patients, including the elderly, veterans and infants.

Philips had taken in thousands of more complaints before initiating a recall and didn’t notify the FDA, the news organizations found. Customers who relied on the continuous positive airway pressure, or CPAP machines, and ventilators reported respiratory illnesses, kidney and liver conditions, and cancer.
In 2023, U.S. Sens. Dick Durbin, D-Ill., and Richard Blumenthal, D-Conn., urged the GAO to investigate the agency’s practices amid the recall, one of the largest of its kind in recent history.
Read More
In a statement, Mr. Durbin called the GAO report “long overdue,” saying it details “the harms caused by drastic staffing cuts” and “how weakened enforcement authority has made it even more difficult for FDA to carry out critical oversight activities.”
The probe, which began last year, found the FDA doesn’t use its authority to force manufacturers to pull defective devices from the market, even though it's been empowered under federal law for decades to take such action.
In the vast number of cases, device makers take the initiative to launch recalls, including 900 in each of the past five years, the GAO said.
Even when companies start the process, the FDA staff — which has weathered significant cuts under the Trump administration — can’t properly ensure that there are no delays or missteps in removing defective devices from the market and communicating with consumers, the report said.
The agency is currently responsible for overseeing more than 190,000 medical devices in the country — an increase of 15,000 since 2016, according to the GAO.
“FDA needs additional resources and staff to adequately protect Americans from unsafe medical devices,” Mr. Blumenthal said in a statement. “Current and future staffing cuts at FDA will only further undermine the agency’s ability to protect people from unnecessary harm.”
The investigation by the Post-Gazette and ProPublica found some patients didn’t learn about the recall of their breathing machines for months or years and continued to use them even as tests showed the foam in the machines was releasing dangerous compounds.
Since 2021, the FDA has received at least 561 reports of deaths associated with the devices, according to the agency’s last update.
Dr. Rita Redberg, a cardiologist and expert on medical device safety, called the FDA’s recall notification system “primitive by today’s standards” and said improvements have been badly needed for years.
“I mean, recall notices are still faxed because the FDA lacks a modern comprehensive data infrastructure for recalls,” she said. “It’s really shocking.”
One former FDA official said he fears the agency’s handling of recalls could become less efficient in the wake of recent staffing cuts.
“I would be worried that the circumstances at FDA are now even worse than portrayed in the report,” said Dr. Peter Lurie, a former FDA associate commissioner who left the agency in 2017.
FDA employees told the GAO they often can’t carry out basic tasks, such as reading status reports submitted by companies while recalls are underway. Those reports detail how many people have been notified about defective devices, the number of products fixed, and the estimated time frame to complete the recall.
In its response to the GAO’s findings, the Department of Health and Human Services, which oversees the FDA, said it would assess the need for additional staff and greater legislative authority to better manage recalls.
The FDA previously defended its handling of the Philips recall, saying it acted as soon as it learned of safety concerns.
Philips has said the original foam caused “no appreciable harm” to patients, but the FDA has challenged that assessment, saying the devices were still capable of causing severe injuries or death.
Last year, the company reached an agreement with the Justice Department, promising to hire an independent safety monitor and undergo regular facility inspections.
Philips also agreed to pay more than $1 billion to settle lawsuits in federal court in Pittsburgh that were launched by thousands of people who say they were injured by the devices.
Earlier this week, Mr. Durbin and U.S. Rep. Jan Schakowsky, D-Ill., introduced legislation that would require the FDA to address some of the GAO’s most pressing concerns.
The bill, among other things, would require the agency to establish an electronic format for recall alerts so that critical information can more easily be shared between companies, the FDA, hospitals and doctors.
“Millions of Americans rely on a medical device to stay healthy,” Mr. Durbin said. “But if their medical device is recalled, patients have the right to know as soon as possible so that they can understand the risks.”



Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.